Skip to content
The Chat Archive
claude-3-5-sonnet-20241022· Anthropic LMArena Human Preference 140K

draft me a clinical research protocol summary

  1. User

    draft me a clinical research protocol summary

  2. Assistant

    Here's a clinical research protocol summary following standard ICH-GCP format:

    Clinical Research Protocol Summary


    Protocol Title

    A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XR-123 in Adult Patients with Type 2 Diabetes Mellitus

    Protocol Number

    XR-123-301

    Sponsor

    PharmaCorp Therapeutics, Inc.

    Phase

    Phase III

    Study Drug

    XR-123 (Novel GLP-1 Receptor Agonist)

    • Dosage Form: Oral tablet
    • Strength: 15mg, 30mg
    • Route: Oral administration
    • Frequency: Once daily

    Primary Objective

    To evaluate the efficacy of XR-123 compared to placebo in reducing HbA1c levels in adult patients with inadequately controlled type 2 diabetes mellitus (T2DM).

    Secondary Objectives

    1. To assess the effect of XR-123 on:
      • Fasting plasma glucose
      • Body weight
      • Blood pressure
    2. To evaluate the safety and tolerability of XR-123
    3. To assess treatment satisfaction and quality of life

    Study Design

    • Multicenter, randomized, double-blind, placebo-controlled, parallel-group study
    • 52-week treatment period
    • 1:1:1 randomization (XR-123 15mg : XR-123 30mg : Placebo)

    Study Population

    Target Enrollment: 750 patients (250 per arm)

    Key Inclusion Criteria:

    1. Adults aged 18-75 years
    2. Diagnosed with T2DM ≥6 months
    3. HbA1c 7.0-10.0%
    4. BMI 25-40 kg/m²
    5. On stable metformin therapy ≥3 months

    Key Exclusion Criteria:

    1. Type 1 diabetes
    2. History of pancreatitis
    3. Cardiovascular event within past 6 months
    4. eGFR <60 mL/min/1.73m²
    5. Liver enzymes >2x ULN

    Study Procedures

    Screening Period (up to 28 days):

    • Informed consent
    • Medical history
    • Physical examination
    • Laboratory assessments
    • ECG
    • Vital signs

    Treatment Period (52 weeks):

    • 8 scheduled visits (Weeks 0, 4, 8, 12, 24, 36, 44, 52)
    • HbA1c assessment at each visit
    • Safety monitoring
    • Patient-reported outcomes
    • Drug dispensing and accountability

    Follow-up Period:

    • 30-day safety follow-up after last dose

    Efficacy Assessments

    Primary Endpoint:

    • Change from baseline in HbA1c at Week 52

    Secondary Endpoints:

    1. Change from baseline in:
      • Fasting plasma glucose
      • Body weight
      • Systolic and diastolic blood pressure
    2. Proportion of patients achieving HbA1c <7.0%
    3. Treatment satisfaction questionnaire scores

    Safety Assessments

    1. Adverse events and serious adverse events
    2. Physical examination
    3. Vital signs
    4. Clinical laboratory tests
    5. ECG
    6. Special interest AEs:
      • Hypoglycemia
      • Gastrointestinal events
      • Pancreatitis
      • Cardiovascular events

    Statistical Considerations

    Sample Size:

    • 750 patients provides 90% power to detect a 0.5% difference in HbA1c between active treatment and placebo
    • Assumes 15% dropout rate

    Analysis Sets:

    • Intent-to-treat (ITT)
    • Per-protocol (PP)
    • Safety population

    Primary Analysis:

    • MMRM (Mixed Model Repeated Measures)
    • Multiple imputation for missing data

    Ethical Considerations

    • IRB/EC approval required
    • Written informed consent mandatory
    • Compliance with ICH-GCP guidelines
    • Regular DSMB safety monitoring

    Study Timeline

    • First Patient First Visit: Q3 2024
    • Last Patient Last Visit: Q4 2025
    • Final Study Report: Q2 2026

    Investigational Sites

    • Approximately 75 sites
    • Countries: United States, Canada, UK, Germany, France, Spain, Italy

    Data Management

    • Electronic Case Report Forms (eCRF)
    • Central laboratory
    • Interactive Response Technology (IRT) for randomization
    • Regular data monitoring and cleaning

    Quality Assurance

    • Monitoring visits
    • Source data verification
    • Protocol deviation tracking
    • Investigator training

    Publication Policy

    Results will be published regardless of outcome in accordance with:

    • ICMJE guidelines
    • ClinicalTrials.gov requirements
    • Sponsor publication policy

    Version: 1.0 Date: June 24, 2025 Status: Draft

    Note: This is a template summary and should be modified according to specific study requirements and sponsor preferences.

    Would you like me to elaborate on any particular section?